| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $9,286,729 ) (Continued on the next page) |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 3 | NIH | 12/11/2025 | $559,022 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289387 | Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence. | 001 | 2 | NIH | 4/16/2026 | $65,711 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299480 | The MIND-BC Study: MIND diet for Breast cancer Cognition | 000 | 2 | NIH | 3/19/2026 | $696,013 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | UH2CA307747 | A multimodal liquid biopsy assay to quantify androgen receptor’s somatic alterations in metastatic castration-resistant prostate cancer. | 000 | 1 | NIH | 3/19/2026 | $225,511 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 3 | NIH | 4/16/2026 | $67,835 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA290007 | An integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response | 001 | 2 | NIH | 4/16/2026 | $62,261 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 001 | 4 | NIH | 4/16/2026 | $53,438 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289581 | Release of interleukin-1a as a mediator of immune evasion in cancer | 001 | 2 | NIH | 4/16/2026 | $56,854 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299434 | Defining the role of MAFG in melanocyte transformation and melanoma development | 000 | 1 | NIH | 4/6/2026 | $607,249 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 000 | 4 | NIH | 4/6/2026 | $441,529 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299899 | Structure-function studies of LAG3 interactions with antibodies and cellular ligands | 000 | 2 | NIH | 4/1/2026 | $549,962 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 001 | 2 | NIH | 3/10/2026 | $113,234 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01ES035723 | H3 histone oxidation is a new posttranslational modification linking heavy metal-induced metabolic changes and oncegenic epigenetic reprogramming | 001 | 4 | NIH | 12/8/2025 | $444,350 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA283730 | Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients | 000 | 3 | NIH | 5/1/2026 | $460,204 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA310579 | Targeting mitochondrial stress responses in melanoma to enhance immunotherapy | 000 | 1 | NIH | 5/1/2026 | $40,393 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA293755 | Program control of CD8+ T cell response to tumors and tumor memory | 000 | 2 | NIH | 5/1/2026 | $549,460 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 4 | NIH | 4/20/2026 | $65,716 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA276496 | Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | 000 | 3 | NIH | 5/4/2026 | $664,357 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 7 | NIH | 1/22/2026 | $417,038 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 6 | NIH | 2/27/2026 | $444,589 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 001 | 7 | NIH | 3/10/2026 | $46,337 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 4 | NIH | 2/27/2026 | $495,033 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 3 | NIH | 1/16/2026 | $610,534 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA290007 | An integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response | 000 | 2 | NIH | 1/19/2026 | $560,358 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 001 | 3 | NIH | 3/5/2026 | $62,113 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 4 | NIH | 12/9/2025 | $480,943 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 000 | 15 | NIH | 12/17/2025 | $304,497 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289387 | Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence. | 000 | 2 | NIH | 12/10/2025 | $591,410 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289581 | Release of interleukin-1a as a mediator of immune evasion in cancer | 000 | 2 | NIH | 12/9/2025 | $511,684 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 001 | 15 | NIH | 4/16/2026 | $33,833 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 4 | NIH | 2/10/2026 | $591,443 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA261598 | Ending Tobacco Use through Interactive Tailored Messaging for Cambodian People Living with HIV/AIDS (EndIT) | 000 | 5 | NIH | 4/1/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA163068 | 2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership | 000 | 13 | NIH | 4/13/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 000 | 6 | NIH | 4/13/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 000 | 5 | NIH | 4/13/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA200464 | Quantitative Imaging Clinical Validation Center at Moffitt Cancer Center | 000 | 8 | NIH | 4/24/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01ES035353 | Suppression of progesterone receptor signaling by heavy metals promotes tamoxifen resistance and metastasis or ER+ breast cancer | 001 | 3 | NIH | 4/14/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DA055298 | Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | 000 | 4 | NIH | 3/25/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 5 | NIH | 3/6/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA252042 | Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | 001 | 5 | NIH | 4/3/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01DE033329 | Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | 000 | 3 | NIH | 3/4/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 000 | 5 | NIH | 2/25/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA252042 | Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | 000 | 5 | NIH | 1/12/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 000 | 5 | NIH | 1/15/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286417 | Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA277834 | Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION) | 000 | 3 | NIH | 3/18/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA277834 | Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION) | 000 | 3 | NIH | 3/18/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 002 | 1 | NIH | 3/10/2026 | -$11,073 |
|
